KMT2D and esophageal squamous cell carcinoma: Tumor suppressors, such as TP53, FAT1, KMT2D and NOTCH1 are often aberrantly expressed in ESCC (2–4), yet limited progress has been achieved in the development of strategies to target these tumor suppressors and no effective molecular drugs are available for treatment of ESCC.